2. Okt. 2019Breakfast Brief

ESMO 2019: “In lung cancer, you have to start with the best treatment first”

Prof. Solange Peters, MD, PhD, CHUV Lausanne, about the OS update of the FLAURA trial and disappointing news for immunotherapy in mesothelioma with the PROMISE-meso trial.

Abstracts in this interview:

  • Ramalingam S et al. Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis. #LBA5_PR
  • Popat S et al. A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. # LBA91_PR

ESMO Congress 2019